Frontlight ResearchEarly access
Trial site
Shengjing Hospital of China Medical University
- 6running trials
- 6closed trials
The trials here
What the 12 trials at this site are about, from their registry records.
- Conditions
- Acute myeloid leukaemia2 trials
- ANCA-associated vasculitis2 trials
- Ulcerative colitis2 trials
- Crohn's disease1 trial
- Follicular lymphoma1 trial
- Heart failure1 trial
- IgA nephropathy1 trial
- Multiple myeloma1 trial
- Multiple sclerosis1 trial
- Myelodysplastic syndromes1 trial
- Phase
- Phase 35 trials
- Phase 1/22 trials
- Phase 11 trial
- Phase 21 trial
- Status
- Completed6 trials
- Recruiting3 trials
- Active, not recruiting1 trial
- Enrolling by invitation1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd2 trials
- Beijing InnoCare Pharma Tech Co., Ltd.1 trial
- Biogen1 trial
- Boehringer Ingelheim1 trial
- Daiichi Sankyo1 trial
- and 6 more
Running trials
Enrolling by invitation
Recruiting
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Recruiting
Recruiting
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Acute myeloid leukaemia1 recruiting
- ANCA-associated vasculitis1 recruiting
- Heart failure1 recruiting
- Multiple myeloma1 recruiting
- Myelodysplastic syndromes1 recruiting
- Ulcerative colitis1 recruiting
Closed trials
Completed
Completed
Completed
Completed
Completed
Completed
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Site data: ClinicalTrials.govUpdated 17 Nov 2026